Nicergoline
- Atc Codes:C04AE02
- CAS Codes:27848-84-6
- PHARMGKB ID:27848-84-6
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Ergotop, Nicergin, Sermion; Bulgaria: Nergolin, Sermion; Czech Republic: Ergotop, Sermion; France: Nicergoline, Sermion; Germany: Cerutil-Nicergolin, Ergobel, Nicergobeta, Nicergolin, Nicerium, Sermion; Greece: Albotyl; Hungary: Ergotop, Sermion; Italy: Nicergolina, Sermion; Latvia: Nicerium, Sermion; Lithuania: Nicerium, Sermion; Luxembourg: Nicerium; Poland: Adavin, Circulat, Nicergolin, Nicerin, Niglostin, Nilogrin, Sermion; Portugal: Sermion; Romania: Gralin, Nicergolina, Nicerium, Sermion, Sinergolin; Slovenia: Adavin; Spain: Sermion, Varson.
Latin America
Argentina: Cergodun, Sermion; Brazil: Sermion; Mexico: Sermion.
Asia
Japan: Bieluzon S, Hirubulin N, Lestmart N, Marileon N, Nicergoline, Salumosin, Sawachion, Selphamin, Sermion, Socwarl N, Vasogoline S, Wincl N.
Drugs Combinations
Nicergoline and Flunarizine
Drug combinations
Chemistry
Nicergoline: C~24~H~26~BrN~3~O~3~. Mw: 484.39. (1) Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-, (8β)-, 5-bromo-3-pyridinecarboxylate (ester); (2) 10-Methoxy-1,6-dimethylergoline-8-β-methanol 5-bromo-nicotinate (ester). CAS-27848-84-6 (1976).
Pharmacologic Category
Vasodilating Agents, Miscellaneous; α-Adrenergic Receptor Blocking Agent; Ergot Derivative. Anti-Dementia Agents; Vasoactive agents. Nootropic. (ATC-Code: C04AE02).
Mechanism of action
Has a wide spectrum of action: (1) as α~1~-adrenoceptor antagonist, induces vasodilation and increases arterial blood flow; (2) enhances cholinergic and catecholaminergic neurotransmitter function; (3) inhibits platelet aggregation; (4) promotes metabolic activity, resulting in increased utilization of oxygen and glucose; (5) has neurotrophic and antioxidant properties.
Therapeutic use
Acute and chronic metabolic vascular cerebral disorders caused by arteriosclerosis, thrombosis, hypertension or cerebral embolism including transient cerebral ischemia, vascular dementia, and headache induced by angiospasm. Acute and chronic peripheral metabolic and vascular disorders (organic and functional arteriopathies of limbs, Raynaud’s disease, syndromes induced by disorders of peripheral blood flow). As supportive therapy in treatment of stroke and hypertensive encephalopathy (parenteral administration).
Pregnancy and lactiation implications
Should be used during pregnancy only when strictly necessary. Not recommended in nursing women.
Unlabeled use
Contraindications
Recent MI, acute hemorrhage, severe bradycardia, impaired orthostatic regulation, increased sensitivity to nicergoline or other components.
Warnings and precautions
Drug should be administered with caution in hyperuricemia, history of gout and/or in treatment with drugs that may interfere with metabolism and excretion of uric acid. Rarely, severe hypotension (predominantly after parenteral administration), dizziness, dyspepsia, hot flushes, skin rash, somnolence or insomnia might occur. Increased concentration of uric acid possible, effect not being related to dose and duration of treatment. Adverse events are mild to moderate.